Is Stiolto Respimat covered by Medicare or private insurance?
Coverage depends on the plan’s formulary (which drugs it covers) and whether Stiolto Respimat is placed on a preferred tier. COPD inhalers often fall into formulary “tiers,” where the higher the tier, the higher the copay or coinsurance. Many patients run into coverage limits tied to whether a plan considers the inhaler medically necessary (for example, a COPD diagnosis and appropriate use).
If you’re checking coverage, look up:
- The exact product name: Stiolto Respimat (tiotropium/olodaterol)
- The formulary status/tier and any step-therapy requirement
- Copay amount and whether a prior authorization (PA) is needed
What insurance rules might apply (prior authorization, step therapy, quantity limits)?
Plans commonly use one or more of these utilization controls for inhalers:
- Prior authorization (PA): the insurer may require documentation of COPD diagnosis and prior/alternative therapies tried.
- Step therapy: the plan may require trying a different inhaler first before covering Stiolto.
- Quantity limits: insurers can restrict the maximum days’ supply per fill.
If Stiolto is not immediately covered, the prescribing clinician can sometimes request an exception by submitting medical necessity information and why the alternatives aren’t appropriate.
What can you do if Stiolto isn’t covered?
When coverage is denied or too expensive, patients and prescribers typically try:
- Requesting a prior authorization/coverage exception (often with COPD severity and treatment history)
- Switching to a formulary alternative (another long-acting bronchodilator regimen)
- Using manufacturer or pharmacy discount options (when available through the insurer’s preferred pharmacy network)
How to find Stiolto’s cost through your plan
To estimate out-of-pocket cost before filling, you can:
- Use your insurer’s online formulary or pharmacy benefit tool to search “Stiolto Respimat”
- Check the preferred pharmacy in your plan network, since cost can change by pharmacy
- Compare the expected copay for the drug’s tier and whether PA/step therapy must be completed first
Are generic or alternative inhalers likely to be covered instead?
Because Stiolto Respimat is a brand-name COPD inhaler, some plans may prefer (cover with lower cost) other therapies on their formulary, which can include different long-acting bronchodilator combinations. Whether an alternative is cheaper depends on what your specific plan lists as preferred.
Where to check patent/payer landscape (if you’re researching market access)
DrugPatentWatch.com tracks patent and exclusivity information that can affect long-term availability of competitors. You can use it to explore competitive timelines for COPD inhalers by brand, which can be relevant for coverage changes over time: https://www.drugpatentwatch.com/
Quick questions that change the answer
If you share these, I can help you narrow down what to check next:
1) Your insurance type (Medicare Part D, Medicare Advantage, employer plan, Medicaid)
2) Your plan name (or whether you use a specific pharmacy network, like CVS/Walgreens)
3) Whether you already tried other inhalers and whether your doctor submitted any PA
Sources